Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 11 of 12, showing 5 Applications out of 57 total, starting on record 51, ending on 55

# Protocol No Study Title Investigator(s) & Site(s)

51.

ECCT/13/07/01   HIVCORE004/N004
    A phase I/IIa clinical trial of universal HIV-1 vaccines pSG2.HIVconsv DNA, MVA.HIVconsv and ChAdV63.HIVconsv in combined regimens in healthy HIV-1/2-negative adults in Nairobi.   
Principal Investigator(s)
1. Prof. Walter Godfrey Jaoko
Site(s) in Kenya
KAVI-KANGEMI RESEARCH SITE
 
View

52.

ECCT/13/04/03   HIV-Malaria Study_A5297
        An Open-Label, Proof of Concept, Randomized Trial Comparing a LPV/r-Based to an nNRTI-Based Antiretroviral Therapy Regimen for Clearance of    Plasmodium falciparum Subclinical Parasitemia in HIV-infected Adults with CD4+ Counts >200 and <350 cells/mm3 .   
Principal Investigator(s)
1. Josphat K. Kosgei
Site(s) in Kenya
1. Kemri Walter Reed Project-Kericho (Kericho county)
2. Moi University Clinical Research Centre (Uasin Gishu county)
 
View

53.

ECCT/12/12/01  
        A pilot study to optimise controlled human malaria infections in humans with varying degrees of prior exposure to malaria using P. falciparum sporozoites administered by needle and syringe   
Principal Investigator(s)
1. Bernhards Ogutu
2. Kevin Marsh
Site(s) in Kenya
Kenya Medical Research Institute, Centre for Clinical Research, Nairobi
 
View

54.

ECCT/12/11/02   Not provided
    A5297: An Open-Label, Proof of Concept, Randomized Trial Comparing a LPV/r-Based to an nNRTI-Based Antiretroviral Therapy Regimen for Clearance of   Plasmodium falciparum Subclinical Parasitemia in HIV-infected Adults with CD4+ Counts >200 and <350 cells/mm3   
Principal Investigator(s)
1. Abraham Mosigisi Siika
Site(s) in Kenya
1. Moi University Clinical Research Centre (Uasin Gishu county)
 
View

55.

ECCT/11/12/04   PENNVAX-G DNA/MVA HIV Vaccine Phase 1 trial
    A Phase I Study of the Safety and Immunogenicity of PENNVAX™-G DNA (Env & Gag) Administered by Intramuscular Biojector® 2000 or by CELLECTRA® Intramuscular Electroporation Device Followed by MVACMDR (HIV-1 CM235 env/ CM240 gag/pol) Boost in Healthy, HIV Uninfected Adults   
Principal Investigator(s)
1. FREDRICK KIPYEGO SAWE
Site(s) in Kenya
KEMRI/Walter Reed Project-Kericho
 
View